{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:53:12Z","timestamp":1770540792942,"version":"3.49.0"},"reference-count":16,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Locally advanced basal cell carcinoma (LA-BCC) is defined as that BCC in which there is radiological confirmation of invasion of certain neighboring structures in depth and also, usually, a BCC that is of a sufficient size and invasion (although there is no radiological demonstration of deep invasion) in which surgery and radiotherapy are not adequate, are insufficient or are contraindicated to achieve the cure of the tumor, either due to characteristics of the tumor itself or of the patient. Sonidegib is indicated for the treatment of adult patients with locally advanced basal cell carcinoma that is not amenable to curative surgery or radiotherapy. Material and methods: This is a retrospective, multicenter and descriptive study in nine centers in Andalusia, Spain. Patients treated with sonidegib for &gt;3 months for locally advanced BCC were included from 1 January 2021 to 1 January 2023. Epidemiological, efficacy and safety data were collected. Results: In the present study, a total of 38 patients were included, with a median age of 76.23 years (range 40\u2013101). Prior treatment was surgery (31.57%; n = 25), radiotherapy (15.78%; n = 6), vismodegib (31.57%; n = 12). Eleven patients had not received prior treatment. LA-BCC were located in the cephalic pole, face or scalp. There was a total response in 9\/38 patients (23.7%), partial response in 25\/38 patients (65.8%) and no response in 4 patients (10.52%). In 6\/34 patients, the dose was reduced to 200 mg every other day until it was discontinued due to adverse effects. The main adverse effects reported were dysgeusia (n = 8), asthenia (n = 8), = 6), muscle spasms (n = 6), alopecia (n = 4) and gastrointestinal intolerance (n = 4). Discussion: Sonidegib is the second iHh authorized for the treatment of adult patients with locally advanced BCC who are not amenable to curative surgery or radiotherapy, based on the results of the phase II clinical trial, BOLT. Sonidegib shows good effectiveness and an acceptable safety profile in routine clinical practice in the sample presented.<\/jats:p>","DOI":"10.3390\/jcm12175631","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T10:49:10Z","timestamp":1693306150000},"page":"5631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"first","affiliation":[{"name":"Hospital Universitario San Cecilio, Instituto Biosanitario de Granada, Ibs, 18016 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Herrera-Acosta","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de la Victoria M\u00e1laga, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Ruiz de Casas","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel M.","family":"Villegas-Romero","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta del Mar, 11009 C\u00e1diz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima G.","family":"Moreno-Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Jaen, 23007 Jaen, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"V\u00edlchez-M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Gal\u00e1n-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Reina Sof\u00eda, IMIBIC, 14004 C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmen","family":"V\u00e1zquez-Bayo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Juan Ramon Jimenez, 21005 Huelva, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Cases-M\u00e9rida","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Jerez, 11407 C\u00e1diz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco M.","family":"Almaz\u00e1n-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital Universitario San Cecilio, Instituto Biosanitario de Granada, Ibs, 18016 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ad.2015.12.008","article-title":"Incidencia y mortalidad del c\u00e1ncer cut\u00e1neo en Espa\u00f1a: Revisi\u00f3n sistem\u00e1tica y metaan\u00e1lisis","volume":"107","author":"Pastushenko","year":"2016","journal-title":"Actas Dermosifiliog."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_3","first-page":"1110","article-title":"Understanding BCC pathogenesis: Treatment advancements and challenges","volume":"12","author":"Goldenberg","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_4","first-page":"167","article-title":"Basal cell carcinoma: Pathogenesis, epidemiology, clinical features, diagnosis, histopathology, andmanagement","volume":"88","author":"Marzuka","year":"2015","journal-title":"Yale J. Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejca.2013.12.013","article-title":"Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease","volume":"50","author":"McCusker","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_6","first-page":"650","article-title":"Metastatic basal cell carcinoma","volume":"29","author":"Spates","year":"2003","journal-title":"Dermatol. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1586\/14737140.2014.895326","article-title":"Locally advanced and metastatic basal cell carcinoma: Molecular pathways, treatment options and new targeted therapies","volume":"14","author":"Alegre","year":"2014","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jid.2012.403","article-title":"Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"133","author":"Chren","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ruiz-Salas, V., Podlipnik, S., Sandoval-Clavijo, A., Sanmartin-Jim\u00e9nez, O., Bernia-Petit, E., Bonfill-Ort\u00ed, M., Bassas-Freixas, P., Yebenes-Marsal, M., Fl\u00f3rez-Men\u00e9ndez, \u00c1., and Sola-Ortigosa, J. (2023). Real-world experience with vismodegib on advanced and multiple BCCs: Data from the RELIVIS study. Dermatology, 1\u20139.","DOI":"10.1159\/000530813"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"T565","DOI":"10.1016\/j.ad.2023.04.022","article-title":"Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study","volume":"114","author":"Deza","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind Phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.jaad.2021.11.041","article-title":"Sonidegib efficacy and tolerability in advanced basal cell carcinoma: A single-center real-life experience","volume":"86","author":"Villani","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"adv00740","DOI":"10.2340\/actadv.v102.1995","article-title":"Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study","volume":"102","author":"Herms","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jaad.2020.12.006","article-title":"Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series","volume":"84","author":"Villani","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","unstructured":"European Public Assessment Report de Odomzo\u00ae (sonidegib) (2023, August 15). Disponible en. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/odomzo-epar-public-assessment-report_en.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40257-023-00763-x","article-title":"Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009\u20132022)","volume":"24","author":"Nguyen","year":"2023","journal-title":"Am. J. Clin. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:41:46Z","timestamp":1760128906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":16,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12175631"],"URL":"https:\/\/doi.org\/10.3390\/jcm12175631","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}